{
  "docId": "019de074-7886-752e-a283-7bf57c077b30",
  "docSlug": "0ac137ebdbf597da5ec73bb0ea218c10",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 31,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a checkmark matrix to highlight the competitive advantages of the proposed drug.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7886-752e-a283-7bf57c077b30/26",
  "deckHref": "/decks/019de074-7886-752e-a283-7bf57c077b30",
  "deckJsonHref": "/decks/019de074-7886-752e-a283-7bf57c077b30.json",
  "deckAnchorHref": "/decks/019de074-7886-752e-a283-7bf57c077b30#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "There is an unmet need in GAD for therapies with rapid onset, high efficacy, and minimal side effects. SSRI/SNRI's are current standard of care for GAD but require 4-6 weeks for onset of effect and have several disadvantages.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a446e85-7ce3-451e-a984-be39da033a97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Benzodiazepines are second-line treatment, offering fast and effective relief, but carrying significant risk of: 1. Sedation 2. Impaired cognition 3. Dependence/addiction",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eec43a16-b84e-44c8-87a0-d23f4c4d0662",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.25,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Note: GABA = Gamma aminobutyric acid, SERT = serotonin transporter, NET = serotonin transporter; MoA = Mechanism of Action; 5HT1a = serotonin 1A receptor; VDCC = voltage dependent calcium channel; TSPO = mitochondrial translocator protein. Source: Publicly available information, including company websites and clinicaltrials.gov, GlobalData, Evaluate Pharma (both as of 2022). 1. DeMartini et al., “Generalized Anxiety Disorder” (2019)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "357076bd-46b5-40d6-b223-9f2caf20cb90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.7,
        "x": 0.25,
        "y": 0.2
      },
      "kind": "table",
      "text": "Comparison table of GAD therapeutic options across safety, onset, and addiction profiles.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ccf660c-a905-4571-a2b7-ed8440295266",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.25,
        "y": 0.05
      },
      "kind": "title",
      "text": "GRX-917 is developed to address unmet need in Generalized Anxiety Disorder (GAD) with rapid onset and favorable safety",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00289d5f-f60d-412d-81a3-df597f8790f7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "eb6064a7-6da7-4808-84fe-72bbd660215e",
      "evidence": "table/data: Comparison table of GAD therapeutic options across safety, onset, and addiction profiles.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "00cd34be-a813-4d3c-9398-1482ce27ae7d",
      "evidence": "Comparison table of therapeutic options against key performance indicators.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}